Search

Reports that guidelines for adequate provision substitution worked out by drug companies and the US Food and Drug Administration (FDA) are being challenge by the print media. Assisting of the FDA on several companies to design their broadcast advertising; Elimination of the brief summary statement in consumer ads; Conditions to allow the removal of brief summary statement in television and radio ads.

The article reports on the changes implemented by the U.S. Food and Drug Agency (FDA) to its new molecular entity (NME) and original biologics license approval tracking to monitor the industry's innovation.

The article reports on the results of a survey by the Union of Concerned Scientist which revealed that more people agree that the U.S. Food and Drug Administration (FDA) is acting effectively to protect public health.

The article reports on the views of U.S. Food and Drug Administration's (FDA) director Janet Woodcock that the Congress must not change the standards for determining a drug's safety and effectiveness under proposed changes to FDA's accelerated approval pathway.

The author offers his opinion on the U.S. Food and Drug Administration which he believes must be politically independent following the government's crackdown on whistleblowers and restrictions on the flow of information.

Reports on the US Postal Service's submission of proposal to increase postage rates of all classes of mail. Increase of paper prices; Reactions on the proposed rate rise.

Reports that Hoechst Marion Roussel is reviewing the data on its defunct cholesterol-lowering drug probucol (Lorelco). `New England Journal of Medicine' report on the benefit of the drug to angioplasty patients.

Reports on the appointment of Harvey Bale as director general of the International Federation of Pharmaceutical Manufacturers Associations. Resignation of bale as senior vice president for international affairs at Pharmaceutical Research and Manufacturers of America.

Reports that Amersham Healthcare is being ordered by the US Food and Drug Administration to stop unapproved use promotions of its diagnostic radiopharmaceutical agent Myoview. Absence of evidence on the safeness and effectiveness of Myoview for other diagnostic procedures.

Reacts on the US Food and Drug Administration proposed rule on pediatric labeling requirement for drugs in the market. Imposition of new studies and labeling for drugs on sale; Prescription of drugs with inadequate pediatric labeling; Advancement of new drug studies in children.

Reports that the US Court of Appeals for the Washington D.C. Circuit agrees with a lower court's pretrial injunction blocking Food and Drug Administration approval of the fertility drug Pergonal from Serono Laboratories. Availability of Ferring Laboratories' Repronal on the market.

Reports on the US Food and Drug Administration panel's recommendation of partial approval of QLT PhotoTherapeutics Inc.'s light-activated drug, Photofrin for the treatment of lung cancer.

Focuses on the reaction of American Dental Association scientific affairs official Cliff Whall over the US Food and Drug Administration's fluoride-toothpaste labeling rule that directs consumers to contact a poison control center after an ingestion of toothpaste more than used for brushing.

Reports on the US Food and Drug Association's requirement of clinical trial testing before it approves any consumer in-home test kit for drugs of abuse.

Reports that the US Food and Drug Administration has publicly made available the list of clinical investigators who have at one time been disqualified, restricted or have made assurances in their use of investigational products.

Reports on the US Food and Drug Association's requirement on drug and biologic manufacturers to include pertinent information to the appropriate use of drugs in the elderly. Creation of a geriatric use subsection in drug labeling.

Reports that sales of acetaminophen and aspirin in Great Britain will be restricted in quantity. Reaction of the Nonprescription Drug Manufacturers Association on the limit; Incidence of aspirin and acetaminophen overdose in the country.

Focuses on the Pharmaceutical Research and Manufacturers of America's proposal to the US Food and Drug Administration stating that drug companies should only report medically confirmed spontaneous reports. Providing of a tabular summary as an appendix to the periodic safety update report.

Reports on the US Food and Drug Administration field compliance program for drug firms with a history of adverse drug reaction reporting problems. Examination of completion and accuracy of ADR submissions; Internet address of the compliance program.

Reports on the depletion of funds at the US Food and Drug Administration's Center for Drug Evaluation and Research. Offices particularly affected; Reaction to Canada's budget-forced closing of its drug laboratories.

Reports on the nomination of Michael Friedman as the US Food and Drug Administration's permanent commissioner.

Reports on the US Food and Drug Administration's Division of Drug Marketing, Advertising and Communications' difficulty in determining acceptable activity when it comes to industry-led focus groups. Sending of a warning letter to Schering and its affiliate Palazzole Associates questioning the conducting of their market research groups for Schering' Vancenase nasal spray.

Presents a brief overview on the meeting between representatives of medical associations and Bayer Corp. and the US Center for Drug Evaluation and Research officials concerning the expansion of the aspirin monograph. Labeling for stable angina pectoris and arteriole revascularization.